@kervio thank you for taking the time to explain this in details. A couple of remarks: the trial is powered now with 21 hospitals, up from 15 in August, and has enrolled 50% in mid October. We may hope that 60% enrollment would be achieved in November when the DSMB will come up with the 45% interim analysis. Also, as you pointed out, SOC ensures better results as 65% of ventilated patients decease down from 85% in April, about 20% improvement. I feel this may help not only placebo but maybe also the patients who receive the treatment. If we improve by the same proportion, 20%, we would be closer to 80% than 75% (9/12) survival rate. This in turn affects the differential. Let’s hope, and be patient GL all
MSB Price at posting:
$3.16 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)